Genomic Studies of Treatment Resistance in Major Depressive Disorder

[1]  M. Bortolomasi,et al.  MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. , 2015, Journal of affective disorders.

[2]  Sarah H. Stephens,et al.  Chronotype and seasonality: morningness is associated with lower seasonal mood and behavior changes in the Old Order Amish. , 2015, Journal of affective disorders.

[3]  M. Bortolomasi,et al.  The role of the potassium channel gene KCNK2 in major depressive disorder , 2015, Psychiatry Research.

[4]  Alyson K. Myers,et al.  Adherence to Antidepressant Combinations and Monotherapy for Major Depressive Disorder: A CO-MED Report of Measurement-Based Care , 2014, Journal of psychiatric practice.

[5]  T. Peters,et al.  Copy number variants and therapeutic response to antidepressant medication in major depressive disorder , 2014, The Pharmacogenomics Journal.

[6]  Chen Zhang,et al.  A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression , 2013, Psychopharmacology.

[7]  Simon C. Potter,et al.  Genome-wide Association Analysis Identifies 14 New Risk Loci for Schizophrenia , 2013, Nature Genetics.

[8]  C. P. Morris,et al.  Dopamine D₃ receptor gene variation: impact on electroconvulsive therapy response and ventral striatum responsiveness in depression. , 2013, The international journal of neuropsychopharmacology.

[9]  C. Zarate,et al.  New paradigms for treatment‐resistant depression , 2013, Annals of the New York Academy of Sciences.

[10]  A. Serretti,et al.  Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  R. Perlis.  A Clinical Risk Stratification Tool for Predicting Treatment Resistance in Major Depressive Disorder , 2013, Biological Psychiatry.

[12]  S. Fekete,et al.  Patients with Difficult-to-Treat Depression Do not Exhibit an Increased Frequency of CYP2D6 Allele Duplication , 2013, Pharmacopsychiatry.

[13]  T. Lehtimäki,et al.  BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression , 2013, Psychiatric genetics.

[14]  K. Tansey,et al.  Contribution of Common Genetic Variants to Antidepressant Response , 2013, Biological Psychiatry.

[15]  A. Serretti,et al.  Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression , 2012, Neuroscience Letters.

[16]  R. Perlis,et al.  Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis. , 2012, The Journal of clinical psychiatry.

[17]  T. Lehtimäki,et al.  Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD , 2011, Neuroscience Letters.

[18]  M. Rietschel,et al.  Variation in GNB3 predicts response and adverse reactions to antidepressants , 2011, Journal of psychopharmacology.

[19]  M. Fava,et al.  Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model , 2011, Psychological Medicine.

[20]  H. Möller,et al.  Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. , 2011, The international journal of neuropsychopharmacology.

[21]  T. Lehtimäki,et al.  Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression , 2010, Neuroscience Letters.

[22]  T. Lehtimäki,et al.  TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response , 2010, Neuroscience Letters.

[23]  T. Lehtimäki,et al.  TPH2 polymorphisms may modify clinical picture in treatment-resistant depression , 2009, Neuroscience Letters.

[24]  T. Lehtimäki,et al.  ACE polymorphism and response to electroconvulsive therapy in major depression , 2009, Neuroscience Letters.

[25]  Mickael Bech,et al.  Estimating the Danish populations' preferences for pharmacogenetic testing using a discrete choice experiment. The case of treating depression. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  R. Goetzel,et al.  Cost burden of treatment resistance in patients with depression. , 2009, The American journal of managed care.

[27]  P. Moorjani,et al.  Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study , 2008, Neuropsychopharmacology.

[28]  T. Lehtimäki,et al.  RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder , 2008, Neuroscience Letters.

[29]  I. Lucki,et al.  Pharmacogenomic Evaluation of the Antidepressant Citalopram in the Mouse Tail Suspension Test , 2006, Neuropsychopharmacology.

[30]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[31]  M. Stein,et al.  Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. , 2006, Psychiatric services.

[32]  M. Eaddy,et al.  Methods for Evaluating Patient Adherence to Antidepressant Therapy: A Real-World Comparison of Adherence and Economic Outcomes , 2006, Medical care.

[33]  T. Lehtimäki,et al.  The Apolipoprotein E Polymorphism Is Not Associated With Response to Electroconvulsive Therapy in Major Depressive Disorder , 2005, The journal of ECT.

[34]  E. Baca-García,et al.  A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. , 2003, The Journal of clinical psychiatry.

[35]  D. Kupfer,et al.  Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. , 2003, The Psychiatric clinics of North America.

[36]  A. Serretti,et al.  Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. , 1998, Journal of psychiatric research.

[37]  A. Rush,et al.  When at first you don't succeed: sequential strategies for antidepressant nonresponders. , 1997, The Journal of clinical psychiatry.

[38]  Shiva M. Singh,et al.  Pharmacogenetic response to antidepressants in a multicase family with affective disorder , 1994, Biological Psychiatry.

[39]  H. Heimann.  Therapy-Resistant Depressions: Symptoms and Syndromes: Contibutions to Symptomatology and Syndromes , 1974, Pharmakopsychiatrie, Neuro-Psychopharmakologie.

[40]  B. Alexanderson,et al.  Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy , 1969, British medical journal.

[41]  L. Rees,et al.  Differentiation of two genetically specific types of depression by the response to anti-depressants. , 1962, Lancet.

[42]  R. Perlis.  Pharmacogenomic testing and personalized treatment of depression. , 2014, Clinical chemistry.

[43]  Y. Fang,et al.  The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice. , 2013, Journal of psychiatric research.

[44]  A. Serretti,et al.  A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. , 2011, Journal of affective disorders.